Navigation Links
Agendia Introduces the SYMPHONY™ Breast Cancer Profile With Paraffin Embedded Tissue
Date:12/6/2011

IRVINE, Calif. and AMSTERDAM, Dec. 6, 2011 /PRNewswire/ -- Agendia, an innovative molecular diagnostics company, today announced the introduction of formalin fixed, paraffin embedded tissue technology applied to their Symphony™ suite of breast cancer assays. Delivering Agendia's tests in a paraffin embedded tissue format offers their customers added convenience along with the superior science, development and validation found in Agendia's breast cancer Symphony suite.

"Agendia's Symphony suite provides physicians with clear insight, helping them to choose a treatment protocol customized for each patient's individual needs," said Agendia's CEO, David Macdonald. "The use of paraffin embedded tissue with these tests will further assist physicians in delivering personalized treatment options."

Agendia's breast cancer Symphony suite of products leverage the predictive and prognostic power of four separate and distinct assays to provide a comprehensive decision support system.  Symphony assists physicians in determining which patients will benefit from chemo therapy, hormonal therapy, or combination therapies, preventing unnecessary suffering from short and long term side effects and burdensome costs to the overall health care system. Symphony includes MammaPrint®, which determines the risk of recurrence;  BluePrint™ determines molecular subtypes; TargetPrint® determines ER, PR and HER2 status; and TheraPrint® identifies alternative types of therapy for metastatic disease.

MammaPrint was the first in vitro Diagnostic Multivariate Index Assay (IVDMIA) to acquire clearance from the US Food and Drug Administration (FDA).  Originally offered for fresh tissue specimens, MammaPrint accurately identifies the risk of disease recurrence for patients with early stage breast cancer.

About Agendia:

Agendia is a leading molecular diagnostic company that develops and markets genomic-based diagnostic products that improve the quality of life for cancer patients and simplifies complex treatment decisions for their physicians. Agendia's Symphony™ suite of breast cancer products is based on the analysis of hundreds of genes in a patient's breast and provides unprecedented biological insight to address complex treatment decisions. Symphony includes MammaPrint, the first and only FDA-cleared IVDMIA breast cancer recurrence assay, BluePrint­­, a molecular subtyping assay, TargetPrint, an ER/PR/HER2 expression assay, and TheraPrint, a therapy selection assay. Together, these tests help physicians determine a patient's individual risk for metastasis, which patients will benefit from chemo or hormonal therapy, and which patients do not require these treatments and can instead be treated with other less arduous and less costly methods.

In addition to the Symphony suite of breast cancer tests, Agendia has a rich pipeline of genomic products in development based on its world-class quantitative gene expression platform. The company also collaborates with pharmaceutical companies to develop companion diagnostic tests in the area of oncology and is a critical partner in the ISPY-2, MINDACT as well as other trials.

Agendia was founded in 2003 as a spin-off of the Netherlands Cancer Institute and is based in Irvine, California, United States, and Amsterdam, the Netherlands. For more information, please visit www.agendia.com.

For further information, please contact:


Ricochet Public Relations
Todd Aydelotte
Tel: +1 212 679 3300 ext. 111
E-mail: todd@ricochetpr.com


'/>"/>
SOURCE Agendia
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Agendia Appoints New CEO and Supervisory Board Member
2. Agendia Receives €1.27 Million in Funding from the EUs Seventh Framework Programme
3. Agendia Inaugurates New State-of-the-Art Genomics Laboratory in Irvine
4. Agendia to Provide Testimony at Public Meeting on FDA Oversight of Laboratory-Developed Tests
5. Agendia to Play Pivotal Role in ISPY-2 Trial for Breast Cancer
6. FDA Broadens Clearance for Agendias MammaPrint(R)
7. /C O R R E C T I O N -- Agendia B.V./
8. Agendias Breast Cancer Recurrence Test MammaPrint Included in International St. Gallen Expert Consensus Recommendations
9. Agendias Breast Cancer Test MammaPrint(R) Identifies New Subset of Low Risk HER2+ Patients
10. Agendias MammaPrint(R) Predicts Response to Neoadjuvant Chemotherapy in Breast Cancer
11. Agendia Supports High Profile CME Symposium and Presents Compelling Data at the 2008 San Antonio Breast Cancer Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... -- , First quarter 2016 adjusted diluted ... million , First quarter reported diluted (GAAP) ... , Company revises 2016 financial guidance; now expects 2016 ... 2016 adjusted diluted non-GAAP earnings per share to range from ... regarding Generics business and manufacturing facility restructuring , ...
(Date:5/5/2016)... , May 5, 2016 Research and ... Imaging in Top 5 EU Markets"  report to their offering.  ... report provides information on the current Positron Emission Tomography (PET) ... Markets (T5 EU), which includes France , ... Spain and the United ...
(Date:5/5/2016)... 2016 Research and ... Systemic Lupus Erythematosus Market and Competitive Landscape ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Systemic Lupus Erythematosus Market and Competitive Landscape ... Systemic Lupus Erythematosus pipeline products, Systemic Lupus ...
Breaking Medicine Technology:
(Date:5/6/2016)... (PRWEB) , ... May 06, 2016 , ... Logically, spring ... other seasons, when the weather is too cold, dry or hot, water on the ... can actually absorb moisture from the surrounding air. There’s only one problem, according to ...
(Date:5/6/2016)... ... 2016 , ... From the Speaker Podium to the Exhibit Floor at Booth#514, ... on managing Customers Engagement at SpeechTek 2016 Event, taking place May 23-25 at the ... Presentation on “5 Customer Engagement Strategies to improve Customer Satisfaction in your ...
(Date:5/6/2016)... ... May 06, 2016 , ... ... Sleepopolis.com . , Since launching in September, 2014 Sleepopolis has resided at ... which now include pillows, sheets, mattress toppers, bed frames, and more. , Founder ...
(Date:5/6/2016)... , ... May 06, 2016 , ... ... arrival of Sovaldi, which made headlines mostly for its cost despite its potential ... and moral questions surrounding the drug—part of a class called direct-acting antivirals (DAAs)—have ...
(Date:5/6/2016)... ... May 06, 2016 , ... Kenneth Cochran, ... of Cardiovascular Institute of the South announced today that Dr. Robert Menuet, Interventional ... of an Intravascular Ultrasound Guided Coronary Atherectomy. , This procedure involves ...
Breaking Medicine News(10 mins):